Table 1
Overview of the biospecimens, their preservatives, and preservation temperatures.
| Biological specimen | Additive/short term preservative | Long term preservation temperature | Number of aliquots à 300 µl | Baseline | 6 months follow up | 1 year follow up |
|---|---|---|---|---|---|---|
| Venous blood | Serum – silicate | –80°C | 20 | x | x | x |
| Plasma – K-EDTA | –80°C | 20 | x | x | x | |
| Plasma Buffy Coat – K-EDTA | –80°C | 4 | x | x | x | |
| Plasma – Na-Citrate | –80°C | 8 | x | x | x | |
| RNA | Paxgene Blood RNA system (BD) | –80°C | 1 Paxgene tube | x | x | |
| Spontaneous urine | none | –80°C | 16 | x | ||
| Left-ventricular biopsies | LN2 | –80°C | 4 biopsies | x | ||
| 4% paraformaldehyde (PFA) | Room temperature (PFA-fixed, paraffin embedded) | 1 biopsy | x | |||
| Rectal swabs | eNAT (guanidine-thiocyanate-based medium) | –80°C | 4 | x | x | |
| Fibroblasts | DMEM + 20% FBS + 8% DMSO | –196°C | 8–12 in 2 ml cryo vials | x |
Table 2
Overview of the clinical data collected.
| Baseline | Clinical discharge | 30 days after intervention* | 6 months follow up | 1 year follow up | 2 years follow up* | 3 years follow up* | 4 years follow up* | 5 years follow up* | |
|---|---|---|---|---|---|---|---|---|---|
| Clinical basic data set | x | x | x | ||||||
| transthoracic echocardiography | x | x | x | ||||||
| 12-lead suface ECG | x | x | x | ||||||
| Cardiac MRI | x | x | |||||||
| Cardiac computed tomography | x | ||||||||
| VARC-2 defined criteria | x | x | |||||||
| 6 minute walking test | x | x | x | ||||||
| NYHA class | x | x | x | x | x | x | x | x | |
| Minnesota Living with Heart Failure Questionnaire | x | x | x | x | x | x | x | x | |
| Re-hospitalisation | x | x | x | x | x | x | x | ||
| Mortality | x | x | x | x | x | x | x | x |
[i] *Assessed via a phone visit.